Abstract:Renal fibrosis is a common pathological feature of chronic kidney diseases (CKD) and its development and progression are significantly affected by epigenetic modifications such as aberrant miRNA and DNA methylation. Klotho is an anti-aging and anti-fibrotic protein and its early decline after renal injury is reportedly associated with aberrant DNA methylation. However, the key upstream pathological mediators and the molecular cascade leading to epigenetic Klotho suppression are not exclusively established. Here we investigate the epigenetic mechanism of Klotho deficiency and its functional relevance in renal fibrogenesis. Fibrotic kidneys induced by unilateral ureteral occlusion (UUO) displayed marked Klotho suppression and the promoter hypermethylation. These abnormalities were likely due to deregulated transforming growth factor-beta (TGFβ) since TGFβ alone caused the similar epigenetic aberrations in cultured renal cells and TGFβ blockade prevented the alterations in UUO kidney. Further investigation revealed that TGFβ enhanced DNA methyltransferase (DNMT) 1 and DNMT3a via inhibiting miR-152 and miR-30a in both renal cells and fibrotic kidneys. Accordingly the blockade of either TGFβ signaling or DNMT1/3a activities significantly recovered the Klotho loss and attenuated pro-fibrotic protein expression and renal fibrosis. Moreover, Klotho knockdown by RNA interferences abolished the anti-fibrotic effects of DNMT inhibition in both TGFβ-treated renal cell and UUO kidney, indicating that TGFβ-mediated miR-152/30a inhibitions, DNMT1/3a aberrations and subsequent Klotho loss constitute a critical regulatory loop that eliminates Klotho's anti-fibrotic activities and potentiates renal fibrogenesis. Thus, our study elaborates a novel epigenetic cascade of renal fibrogenesis and reveals the potential therapeutic targets for treating the renal fibrosis-associated kidney diseases.

Natural Products Against Renal Fibrosis via Modulation of SUMOylation

Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems

MiR-155-5p Promotes Renal Interstitial Fibrosis in Obstructive Nephropathy Via Inhibiting SIRT1 Signaling Pathway

Exploring potential targets for natural product therapy of DN: the role of SUMOylation

SUMO: A new perspective to decipher fibrosis

Bisdemethoxycurcumin Protects Against Renal Fibrosis Via Activation of Fibroblast Apoptosis

Emerging Roles Of Long Non-Coding Rnas In Renal Fibrosis

Exosome-mediated renal protection: Halting the progression of fibrosis

TGF-β/Smad Signaling Pathway in Tubulointerstitial Fibrosis

Defining Therapeutic Targets for Renal Fibrosis: Exploiting the Biology of Pathogenesis

Discovery of Natural Products Alleviating Renal Fibrosis with a Viscosity-Responsive Molecular Probe

Druggability of lipid metabolism modulation against renal fibrosis

Metabolic reprogramming and renal fibrosis: what role might Chinese medicine play?

Renal fibrosis: New insights into the pathogenesis and therapeutics

TGFβ-incurred Epigenetic Aberrations of Mirna and DNA Methyltransferase Suppress Klotho and Potentiate Renal Fibrosis

Cellular senescence and the senescence-associated secretory phenotype: Potential therapeutic targets for renal fibrosis

Targeting the Wnt/β-Catenin Signaling Pathway as a Potential Therapeutic Strategy in Renal Tubulointerstitial Fibrosis

GSK3β-dependent Lysosome Biogenesis: an Effective Pathway to Mitigate Renal Fibrosis with LM49

Targeted Inhibition of Endoplasmic Reticulum Stress: New Hope for Renal Fibrosis

Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression

Sulforaphane Alleviates Renal Fibrosis Through Dual Regulation on Mtor-Mediated Autophagy Pathway